What exactly is frontloading with a long-ester compound like Methenolone Enanthate?

Frontloading means administering a larger-than-maintenance dose at the start of a cycle to rapidly elevate plasma concentrations toward steady state. With long esters like Methenolone Enanthate, flat weekly dosing takes four to six weeks to reach consistent blood levels; a properly calculated front load achieves near-steady-state concentrations within the first seven days, giving meaningful muscle-sparing activity from the outset of the protocol.

How do I calculate the correct loading dose when using Primo 150?

The standard loading-dose calculation multiplies the intended weekly maintenance dose by a factor between 1.5 and 2.0, based on the compound's half-life relative to the dosing interval. For Primo 150 at a 300 mg/week maintenance target, the week-one load is 450–600 mg, delivered as two equal injections three to four days apart. At 150 mg/ml, a 600 mg load requires 4 ml total — split evenly as two 2 ml injections for site-comfort management.

Is a kickstart approach with the enanthate ester genuinely worthwhile compared to adding an oral compound in week one?

Yes, for users avoiding hepatotoxic oral agents, an enanthate frontload is a clinically sound alternative kickstart. The frontloaded Methenolone Enanthate reaches pharmacologically active concentrations within 48–72 hours of the elevated first dose, bypassing the four-to-six-week lag of flat dosing without introducing the liver-stress profile associated with 17-alpha-alkylated oral steroids. The twice-weekly injection schedule remains unchanged, so no additional injection-frequency burden is added.

How should Primo 150 vials be stored after the first use, and what is the shelf life once opened?

Store Primo 150 vials at room temperature between 15–25 °C, away from direct light and moisture. Once the rubber stopper has been punctured, the vial remains usable for the duration of the printed expiry date provided the stopper is wiped with 70% isopropyl alcohol before every draw and the vial shows no visible particulate matter or cloudiness. Refrigeration is not required but is acceptable; allow the oil to reach room temperature before drawing to reduce viscosity and improve injection flow.

Can an insulin syringe be used to draw and inject Primo 150 from the 10 ml vial?

Insulin syringes (typically 0.5 ml or 1 ml, 27–29 gauge) can be used for drawing and injecting Primo 150 in low-volume doses such as 0.5–1 ml per site, though the higher oil viscosity at 150 mg/ml may require warming the vial slightly and accepting a slower draw rate. For loading doses exceeding 1.5 ml per injection site, a standard 3 ml luer-lock syringe with a 23–25 gauge, 1–1.5 inch needle is more practical and reduces draw time considerably. (2) angle_used

Coach Recommended

Military Pharma

Primo 150 150mg/ml 10ml Vial by Military Pharma

Name: Primo 150 150mg/ml 10ml Vial by Military Pharma
Brand: Military Pharma
SKU: INJ-METE-MIL-150-015
Price: 55.00 EUR
Availability: InStock

Military Pharma Primo 150 delivers Methenolone Enanthate at 150 mg/ml in a 10 ml multi-dose vial — a concentration specifically suited to frontloading protocols, where an elevated opening dose accelerates the attainment of stable plasma levels in the first week of a cycle. Compared to standard 100 mg/ml formulations, the 150 mg/ml density reduces the volume per loading dose, making the initial injection more comfortable while delivering the same elevated milligram load required by classical frontloading calculations. Sterility and potency are verified through independent HPLC quantification and LAL-method endotoxin testing on every production batch.

€55.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

150 mg/ml concentration reduces the total injection volume required during the frontloading week compared to 100 mg/ml alternatives
Single 10 ml vial contains sufficient Methenolone Enanthate to complete a loading week plus a full 14-week maintenance phase without opening a second vial
HPLC-verified potency within ±2% of label claim ensures that frontload dose calculations remain accurate and reproducible across the batch
Methenolone Enanthate delivers nitrogen-retention support from the first week when frontloaded, reducing early-cycle catabolism during caloric restriction
Oil-based depot formulation sustains twice-weekly injection scheduling throughout the entire cycle, including the loading phase — no frequency change required
LAL endotoxin assay on each production batch confirms safety thresholds are met, supporting confidence in higher opening-dose administration
Coach Recommended for athletes who prefer an injectable-only kickstart strategy free from oral hepatotoxic agent exposure

Phase	dosage	Note
Loading / Frontload (Week 1)	450–600 mg (3–4 ml of Primo 150)	Split into two equal injections 3–4 days apart; represents 1.5–2× the intended weekly maintenance dose
Early Maintenance (Weeks 2–4)	300–400 mg/week (2–2.67 ml of Primo 150)	Transition to standard bi-weekly schedule; blood levels stabilise as frontload depot releases
Full Maintenance (Weeks 5–14)	300–400 mg/week (2–2.67 ml of Primo 150)	Sustain consistent twice-weekly injections; adjust based on bloodwork response at week 4–6 assessment
Taper / Final Weeks (Weeks 15–16, optional)	150–200 mg/week (1–1.33 ml of Primo 150)	Optional reduction to ease transition; relevant if PCT initiation timing is being managed against final injection date

Key takeaways

Calculate your week-one loading dose at 1.5–2× the intended maintenance weekly amount.
Use 150 mg/ml density to keep loading-dose injection volumes manageable across two sites.
Begin the standard twice-weekly maintenance schedule from week two without changing frequency.
Verify every vial's concentration via HPLC certification before applying frontload calculations.
Store opened vials below 25 °C and swab the stopper before each draw to preserve sterility.

Frontloading Methenolone Enanthate: Why Concentration Matters

Primo 150 is a sterile, oil-based injectable formulation of Methenolone Enanthate at 150 mg/ml designed to support structured frontloading strategies that compress the build-up phase of long-ester anabolic cycles. Frontloading is a dosing technique in which the first one or two injections of a cycle carry a higher-than-maintenance milligram load — typically double the intended weekly dose — so that plasma concentrations approach the eventual steady-state target within days rather than the four-to-six weeks it would otherwise take with flat weekly dosing. With standard 100 mg/ml products, a 600 mg loading dose requires a 6 ml injection volume; at 150 mg/ml, the same 600 mg fits into 4 ml, a meaningful comfort reduction when split across two sites.

The Loading Dose Calculation for Primo 150

The classical frontload formula holds that the loading dose should approximate the total milligrams that would accumulate over one half-life of the ester under a steady weekly schedule. For Methenolone Enanthate, published pharmacokinetic references assign an effective half-life of approximately 10–14 days, which means that without frontloading, users reach functional steady-state only in weeks four to six. A coach-recommended frontload for Primo 150 sets the week-one dose at 1.5–2× the intended weekly maintenance dose, administered across two equally spaced injections 3–4 days apart, then transitions to the standard bi-weekly maintenance schedule from week two onward. Military Pharma's 10 ml vial provides sufficient volume to execute a full 16-week protocol — including an opening loading week — without requiring a second vial purely for the kickstart phase.

Kickstart Rationale and Practical Cycle Design

Primo 150 functions as its own kickstart compound rather than relying on a fast-acting oral agent during the build-up window. Coaches who prefer to avoid oral hepatotoxicity risk recommend this approach when the primary goal is lean tissue preservation during a caloric deficit: Methenolone Enanthate contributes nitrogen-retention support from week one rather than week four, a difference that is particularly relevant on contest-prep timelines of 12–16 weeks where early catabolism matters. Compared to pairing a short-ester acetate version as a kickstart, the enanthate frontload removes the transition injection-frequency burden, keeping the schedule at a consistent twice-weekly cadence throughout the entire cycle. HPLC batch testing by Military Pharma confirms that each vial contains Methenolone Enanthate within ±2% of the declared 150 mg/ml concentration — a precision standard that makes dose calculations from the frontload formula reliable rather than approximate.

Usage

CALCULATE YOUR LOADING DOSE FIRST: Multiply your intended weekly maintenance dose by 1.5–2.0 to determine the week-one frontload milligram total. Divide the result by 150 to convert to millilitres from this vial.
PREPARE THE VIAL: Inspect for clarity and absence of particulate matter. Warm the vial gently in your hands for 60 seconds to reduce oil viscosity, then wipe the rubber stopper with a 70% isopropyl alcohol swab and allow it to air-dry for 10 seconds before inserting the draw needle.
DRAW THE LOADING DOSE: Use a 3 ml luer-lock syringe with an 18-gauge draw needle for efficient oil extraction. Draw the calculated volume, remove the draw needle, and attach a fresh 23–25 gauge, 1–1.5 inch injection needle before proceeding.
SPLIT ACROSS TWO SITES FOR WEEK-ONE COMFORT: Divide the total loading-dose volume equally between two injection sites — for example, left and right ventrogluteal or gluteus maximus — to keep the per-site injection volume within the 2 ml comfort threshold.
SCHEDULE WEEK-ONE INJECTIONS 3–4 DAYS APART: Administer the first loading injection on day 1 and the second on day 4 or 5 of week one. From week two onward, settle into a consistent Monday/Thursday or Tuesday/Friday twice-weekly schedule for maintenance dosing.
STORE THE VIAL AND MONITOR BLOOD LEVELS: After each draw, recap with a clean stopper cover or keep the vial in a clean, light-protected environment at 15–25 °C. Schedule a bloodwork panel at weeks 4–6 to confirm that plasma levels have stabilised as expected from the frontload, and adjust the maintenance dose if indicated.

Warnings

Contraindications: Primo 150 is contraindicated in individuals with known or suspected androgen-dependent neoplasia, active or prior liver disease, hypercalcaemia, and women who are pregnant or breastfeeding. Male patients with a history of cardiovascular events should seek physician assessment before initiating any androgen-based protocol involving frontloading, as the elevated opening-dose phase transiently raises androgenic load above the maintenance level.

Side Effects: Reported adverse effects associated with Methenolone Enanthate include suppression of endogenous testosterone production (dose- and duration-dependent), mild androgenic effects such as increased sebum production and, in genetically predisposed users, accelerated scalp hair thinning. The frontloading phase may concentrate these androgenic signals into the first two weeks; users sensitive to androgenic effects should consider a conservative 1.5× load factor rather than 2×. Injection-site discomfort is possible with volumes approaching 2 ml per site; ventrogluteal administration reduces local reaction risk.

Monitoring: Obtain a full bloodwork baseline — including total testosterone, LH, FSH, haematocrit, lipid panel, and liver enzymes — before the loading injection. Repeat the panel at week 4–6 to capture the post-frontload steady-state picture. Haematocrit elevation above 52% warrants dose reduction or temporary cessation. Lipid monitoring is particularly relevant during caloric-restriction cycles, where dietary fat limitation may amplify androgen-driven LDL shifts.

PCT: Endogenous testosterone suppression induced by Methenolone Enanthate requires structured PCT following cycle cessation. Because the enanthate ester produces a prolonged depot release, allow a clearance window of approximately 14–18 days after the final injection before beginning SERM-based PCT (typically tamoxifen or clomiphene at standard clinical reference doses). The extended clearance consideration applies regardless of whether a frontload was used, as the last maintenance doses — not the loading dose — determine the post-cycle depot.

Frequently asked questions

What exactly is frontloading with a long-ester compound like Methenolone Enanthate?: Frontloading means administering a larger-than-maintenance dose at the start of a cycle to rapidly elevate plasma concentrations toward steady state. With long esters like Methenolone Enanthate, flat weekly dosing takes four to six weeks to reach consistent blood levels; a properly calculated front load achieves near-steady-state concentrations within the first seven days, giving meaningful muscle-sparing activity from the outset of the protocol.
How do I calculate the correct loading dose when using Primo 150?: The standard loading-dose calculation multiplies the intended weekly maintenance dose by a factor between 1.5 and 2.0, based on the compound's half-life relative to the dosing interval. For Primo 150 at a 300 mg/week maintenance target, the week-one load is 450–600 mg, delivered as two equal injections three to four days apart. At 150 mg/ml, a 600 mg load requires 4 ml total — split evenly as two 2 ml injections for site-comfort management.
Is a kickstart approach with the enanthate ester genuinely worthwhile compared to adding an oral compound in week one?: Yes, for users avoiding hepatotoxic oral agents, an enanthate frontload is a clinically sound alternative kickstart. The frontloaded Methenolone Enanthate reaches pharmacologically active concentrations within 48–72 hours of the elevated first dose, bypassing the four-to-six-week lag of flat dosing without introducing the liver-stress profile associated with 17-alpha-alkylated oral steroids. The twice-weekly injection schedule remains unchanged, so no additional injection-frequency burden is added.
How should Primo 150 vials be stored after the first use, and what is the shelf life once opened?: Store Primo 150 vials at room temperature between 15–25 °C, away from direct light and moisture. Once the rubber stopper has been punctured, the vial remains usable for the duration of the printed expiry date provided the stopper is wiped with 70% isopropyl alcohol before every draw and the vial shows no visible particulate matter or cloudiness. Refrigeration is not required but is acceptable; allow the oil to reach room temperature before drawing to reduce viscosity and improve injection flow.
Can an insulin syringe be used to draw and inject Primo 150 from the 10 ml vial?: Insulin syringes (typically 0.5 ml or 1 ml, 27–29 gauge) can be used for drawing and injecting Primo 150 in low-volume doses such as 0.5–1 ml per site, though the higher oil viscosity at 150 mg/ml may require warming the vial slightly and accepting a slower draw rate. For loading doses exceeding 1.5 ml per injection site, a standard 3 ml luer-lock syringe with a 23–25 gauge, 1–1.5 inch needle is more practical and reduces draw time considerably. (2) angle_used

Manufacturer

Military Pharma's packaging architecture for the Primo 150 range centres on the 10 ml multi-dose vial format — a deliberate choice over single-use ampoules for protocols requiring repeated weekly access over extended cycles. The vial specification includes a bromobutyl rubber stopper with an aluminium crimp seal, selected for chemical compatibility with the oil-based vehicle used at 150 mg/ml and for resistance to repeated needle puncture without generating coring particulates. Each vial is nitrogen-purged prior to sealing to eliminate dissolved oxygen that could degrade Methenolone Enanthate over the product's shelf life. Label printing integrates batch-specific traceability codes linked to the corresponding HPLC and LAL certificates of analysis, allowing end-users to cross-reference the documented potency and endotoxin results for their specific production lot.

Product details

Brand	Military Pharma
Active ingredient	methenolone enanthate
Also known as	Primobolan Depot, Primo, Methenolon Enanthat, Primo 150, Military Pharma Primobolan Depot
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-METE-MIL-150-015

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Primobol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Primobol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Primobol by Balkan Pharmaceuticals delivers Methenolone Enanthate at 100 mg/ml across ten glass-fusion sealed, single-dose ampoules — a format rooted in the original Schering AG clinical presentation that has defined this compound since its 1960s introduction for muscle-wasting indications. The 100 mg/ml concentration reflects the benchmark established during Methenolone's first decade of human clinical use, situating Primobol as a direct continuation of a molecule with more than sixty years of documented pharmacological history. Each ampoule is manufactured under GMP Annex 1 aseptic conditions at Balkan Pharmaceuticals' Chișinău facility; HPLC potency analysis and LAL endotoxin screening are completed at batch level before release.

€55.00

Rimobolan 100mg/ml 1x1ml Ampoules by Schering

GMP Standard

Rimobolan 100mg/ml 1x1ml Ampullen by Schering

Rimobolan by Bayer is a pharmaceutical-grade injectable anabolic agent delivering Methenolone Enanthate at 100 mg/ml in a single-use 1 ml glass ampoule, produced under EU Good Manufacturing Practice regulations governed by the European Medicines Agency (EMA) framework. Each batch undergoes rigorous release testing — including HPLC-based potency verification and LAL (Limulus Amebocyte Lysate) endotoxin screening — before leaving Bayer's licensed production site. Quality assurance is built into every stage: from raw-material qualification through in-process controls to final certificate of analysis.

€6.00

High Concentration

Etho-Primobolan 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Primobolan by Beligas Pharmaceuticals is a Methenolone Enanthate injectable at 100mg/ml in a 10ml multi-dose vial, engineered to integrate seamlessly into evidence-informed modern cycling strategies — whether as a base compound, a dry-tissue phase anchor, or a bridging agent between heavier blasts. Its long-acting ester supports once- or twice-weekly injection schedules that align with the structured periodisation models favoured by contemporary competitive and recreational athletes. Quality is verified across the full production chain: each batch undergoes HPLC potency assay and LAL endotoxin testing under Beligas's GMP-certified manufacturing framework.

€68.00

Long-Acting Formula

Primabolin-100 100mg/ml 10ml Vial by BM Pharmaceuticals

Primabolin-100 is an oil-based injectable anabolic agent delivering Methenolone Enanthate at 100mg/ml — a concentration engineered for predictable, sustained plasma release governed by the enanthate ester's extended pharmacokinetic profile. With an active half-life of approximately 10–14 days, blood concentrations remain stable between injections, eliminating the rapid oscillations characteristic of short-ester Methenolone preparations. Quality assurance is embedded at the batch level: every 10ml vial passes HPLC potency verification and LAL endotoxin testing within a GMP-certified production environment operated by BM Pharmaceuticals.

€63.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00